Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy-Reference-Cited by-同舟云学术

Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy

Published:2020-05-26 Issue:9 Volume:99 Page:2141-2148
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Maeshima Akiko Miyagi^ORCID,Taniguchi Hirokazu,Fujino Takahiro,Saito Yo,Ito Yuta,Hatta Shunsuke,Yuda Sayako,Makita Shinichi,Fukuhara Suguru,Munakata Wataru,Suzuki Tatsuya,Maruyama Dai,Izutsu Koji

Funder

Japan Agency for Medical Research and Development Fund

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00277-019-03853-1.pdf

Reference19 articles.

1. Maloney DG (2006) Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 366:2008–2016

2. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS (2010) Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 95:135–143

3. Maloney DG, Grillo-Lopez AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 90:2188–2195

4. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 15:3266–3274

5. Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M (2006) The epitope recognized by rituximab. Blood 108:1975–1978

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cluster of Differentiation Markers and Human Leukocyte Antigen Expression in Chronic Lymphocytic Leukemia Patients: Correlations and Clinical Relevance;Current Issues in Molecular Biology;2024-09-11

2. Complete response using the EZH2 inhibitor tazemetostat against multiple relapsed follicular lymphoma in the leukemic phase;International Cancer Conference Journal;2024-08-21

3. Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2;International Journal of Clinical Oncology;2024-03-17

4. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy;Virchows Archiv;2024-02-13

5. Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma;Frontiers in Immunology;2023-01-26